Materiality
75.25
Source
External coverage
Decided
2026-05-27
CordenPharma’s planned acquisition of AmbioPharm is a positive sector read-through for peptide CDMOs and pharma-services capacity, as it adds U.S. and Shanghai peptide API manufacturing, broadens complex-peptide capabilities, and increases supply optionality for clinical and commercial customers.